Nuvation Bio agreed to acquire portfolio company AnHeart Therapeutics in an all-stock transaction.
AnHeart Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision oncology therapeutics
AnHeart Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision oncology therapeutics. The company's main offerings include a pipeline of drugs targeting specific genetic mutations in various cancers, such as non-small cell lung cancer, glioma, cholangiocarcinoma, and other tumors. These therapeutics are designed to inhibit certain proteins or pathways involved in cancer progression.